According to the information received from the contract laboratory that performed the studies, namely, KARD Scientific, FluCide drug candidate designed for oral administration has shown strong efficacy in
With the IND approval, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases. Apexigen president and CEO Dr. Xiaodong Yang said, "It
According to the transaction, Biogen will invest in Regulus and make upfront and milestone payments. Biogen corporate development executive vice president Steven Holtzman said that utilizing new technology
The trial will evaluate the safety and immunogenicity of the H5N1 vaccine, combined with IDRI’s Glucopyranosyl Lipid A ("GLA") adjuvant. Each study participant in the trial will receive
The patent will provide protection for LOR-253 composition of matter along with the coverage of Lorus lead antimicrobial small molecule LOR-220, which is used to treat drug resistant
As part of the agreement, Merck will bear the costs involved in evaluating the candidate, which Arrowhead obtained from Alvos Therapeutics in April 2012. Arrowhead president and CEO
The patent was awarded based on FDA-authorised clinical study, which showed that the non-toxic dietary supplement (PHC) contributed to healthy outcome for men with recurrent prostate cancer. The
The screening service combines CeeTox in vitro toxicity screening and CDI’s iCell Cardiomyocytes to provide a profile of drug-induced cardiac toxicity early in the drug development cycle. CeeTox
Under the agreement, Zenobia will provide ADDF’s researchers with access to its discovery platform including a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect
Proximagen’s pipeline includes many programs which are in various stages of development across a number of therapeutic classes including CNS, inflammation, oncology and ophthalmology. The acquisition will enable
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.